Earlier today, Coala-Life announced the board’s decision to file for bankruptcy.
Redeye comments on Coala-Life’s latest development: the company has secured liquidity of cSEK27m through a combination of converting and par...
Redeye updates its estimates and valuation following Coala Life’s recent rights issue, securing cSEK55m in growth capital and resulting in a...
Redeye comments on Coala Life’s Q3’23 report, noting that the reported figures are in line with the previously disclosed preliminary figures...
Redye comments on the proposed rights issue of approximately SEK75m and bridge financing that was announced earlier today by Cola Life.
Redeye provides its commentary on Coala Life based on August’s recently released Key Performance Indicators (KPIs).
Redeye comments on today’s news that Coala Life is initiating a cost-reduction program to reduce the company’s total costs by around 30%.
Redeye comments on Coala Life’s Q2’23 report, noting stable sales progress driven mainly by increased invoice value.
Redeye comments on Coala Life's directed issue of cSEK17m.
Redeye provides its commentary on Coala Life based on the recently released Key Performance Indicators (KPIs) for June.
Redeye provides an update following the Q1’23 report from Coala Life.
Redeye comments on Coala Life’s Q1’23 report, in which we note strong growth, a fast ramp-up in active clinics and an average invoice value ...
Redeye sees the Q4 report from Coala Life boosting our confidence in the outlook for the company and underpinning its pivot towards managed ...
Redeye comments on Coala Life’s Q4’22 report, in which sales increased by c80% over the previous quarter.
Earlier this morning, Coala Life proposed a rights issue of units, corresponding to cSEK101m, guaranteed to 75% and consisting of new shares...
Redeye comments on today’s news from Coala Life where the company states that it will start to report Key Performing Indicators (KPI’s) for ...
Redeye is currently reviewing our fair value range and estimates for Coala Life.
Redeye comments on Coala Life’s Q2’22 report and the acquisition of Vitrics.
Redeye comments on Coala Life’s Q1’22 report. With its ongoing US expansion and the recent 510(k) approval for auscultation and monitoring o...
Redeye endorses Coala Life receiving a new 510(k) approval for its Coala Heart Monitor to be used for auscultation and monitoring of patient...
Redeye comments on the outcome of the completed rights issue and adjusts its fair value range accordingly.
Redeye gives a short comment on the announced rights issue of approximately SEK 150m.
Redeye is encouraged to learn that Coala Life has signed RPM agreements with 10 new US clinics.
Redeye comments on Coala Life’s Q4’21 report as well as today’s announcement regarding the intention to carry out a fully underwritten, pref...
Redeye is encouraged to learn that a health economic analysis carried out by the Swedish Dental and Pharmaceutical Benefits Agency shows cos...
